India'a largest pharmaceutical company Ranbaxy Laboratories Ltd has entered into a collaborative research agreement with the Department of Biotechnology (DBT), New Delhi, in the area of New Drug Discovery Research (NDDR).

The research will be conducted under the aegis of DBT's major initiative in the area of tuberculosis and three major areas identified in the program are: - Development of Diagnostics - Development of Vaccines - Development of Drugs.

Under the alliance, Ranbaxy will develop novel drugs, using inhibitor design for novel targets / pathways /proteins etc.

On the other hand, DBT will support the project with a financial grant, for a period of 3 years in the first phase of the alliance. On identification of a lead molecule, DBT and Ranbaxy will jointly support its clinical development. A joint Steering Committee will be constituted to direct, manage and coordinate the collaboration.

Recently, Ranbaxy Laboratories has launched 'BONISTA- Teriparatide' injection used in the treatment of Osteoporosis disease in collaboration with Hyderabad-based Virchow Biotech Pvt. Ltd.